4th Annual eMarketing Summit Europe 2009

eyeforpharmaApril 27-28, 2009, Munich, Germany.
eyeforpharma's leading eMarketing Summit returns for it's forth successful year with a new format and new concepts for 2009, you'll hear from the most experienced and innovative eMarketing experts and enjoy an interactive hands-on learning experience.

Join the 2009 Summit and get fresh perspectives on how to revitalise your online campaigns by introducing better measurement, coordination and execution strategies into your Marketing Mix.

At no other time and in no other place can you find such a high concentration of know-how and innovative ideas in one venue!

Some of the hot topics to be adressed in the Summit:

  • Changing role of eMarketing teams: profile, training and development: Get the answers to such questions as: What is the profile of people responsible for your on-line strategies? How many people should be involved and how to train and develop them?
  • Branding and eMarketing: The move from product strategy to implementation: Learn new ways to better align your brand plan and digital tactics to facilitate cohesive relationships between your customers and brands.
  • Physician’s communities and physicians search behaviour: Understand how physicians recently use and feel about on-line medical information in order to identify their unmet needs for tools and services.
  • New tools for better targeting. What Web 2.0 can offer to build long-term relationships?: Find the answers to essential questions about how to use Web 2.0 to your benefit and form a better overview of its potential.
  • Search Engine Marketing: How to improve its performance? Hear specific examples on how companies implement SEM projects to meet your client’s needs.

For further information, please visit:
http://www.eyeforpharma.com/emarketing/

About eyeforpharma
eyeforpharma is a leading global source of information for the pharmaceutical industry. Our reputation has been built on quality, in-depth conferences that have distinguished themselves from competitors by the depth and breadth of research we put into each conference to ensure it is covering the hottest and most pertinent issues of the industry. Months are spent talking directly to senior executives in the industry, as well as relevant consultants and journalists and well respected solutions providers. For more information, please visit www.eyeforpharma.com.

Most Popular Now

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...